AbbVie Stock News

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy, especially as the market multiples look elevated from a historical perspective. Progress on its treatments, particularly for Inflammatory Bowel Disease, is encouraging. This is key, as the market for the disease is growing with its rising incidence impacted by lifestyle factors. The company's re...

AbbVie delivered Y/Y growth in the second quarter despite Humira's decline, with Skyrizi and Rinvoq as key growth drivers, achieving 45% and 56% Y/Y growth, respectively. I expect Skyrizi to become a bigger product for AbbVie than Humira was at its peak in 2021. Skyrizi's robust efficacy and good safety in psoriasis, psoriatic arthritis, and inflammatory bowel diseases support its strong long-t...

AbbVie is a Dividend King that has proven it can successfully navigate challenges. Lowe's Companies is a great stock to own over the long run because homes will always need to be fixed up.

Aldeyra Therapeutics' Reproxalap eye drop for Dry Eye Disease has new positive data for the second NDA attempt. Aldeyra has an option agreement with AbbVie, potentially leading to significant milestone payments and a 60%/40% partnership if FDA approval is granted. Reproxalap offers immediate and long-term relief, a significant advantage over existing therapies like Xiidra and Restasis, enhancin...

During times of market volatility, it's always good for long-term investors to take a breath and zoom out. That doesn't mean getting out of the markets as fast as possible.

Investment activity in July focused on Business Development Companies, with $2,000 added to the market. Adjusted dividend income in July of $709, up 19% Y/Y and down 4% sequentially. Main picks included Blackstone Secured Lending, Ares Capital and Owl Rock Capital.

AbbVie is one of my biggest winners and a top 10 holding in my portfolio. The company's increasing contributions from Skyrizi and Rinvoq pushed net revenue higher in Q2. AbbVie maintains its A- credit rating from S&P on a stable outlook.

AbbVie has shown strong growth, especially in immunology and oncology, with Skyrizi and Rinvoq driving impressive sales and long-term growth potential. Despite Humira's patent loss, AbbVie has managed a "soft landing" and continues to innovate, particularly in neuroscience and oncology. The company offers a solid dividend with a 51% payout ratio and consistent growth, making it attractive for c...